期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Efficacy of afatinib in a patient with rare EGFR(G724S/R776H)mutations and amplification in lung adenocarcinoma:A case report
1
作者 shu-yan he Qing-Feng Lin +3 位作者 Jie Chen Gui-Ping Yu Jun-Ling Zhang Dong Shen 《World Journal of Clinical Cases》 SCIE 2021年第6期1329-1335,共7页
BACKGROUND The most common EGFR mutations are in-frame deletions in exon 19 and point mutations in exon 21.Cases with classical EGFR mutations show a good response to EGFR tyrosine kinase inhibitors(TKIs),the standard... BACKGROUND The most common EGFR mutations are in-frame deletions in exon 19 and point mutations in exon 21.Cases with classical EGFR mutations show a good response to EGFR tyrosine kinase inhibitors(TKIs),the standard first-line treatment.With the development of next generation sequencing,some uncommon genomic mutations have been detected.However,the effect of TKIs on such uncommon EGFR mutations remains unclear.CASE SUMMARY Here,we report a case of rare EGFR co-mutation in non-small cell lung cancer and the efficacy of afatinib on this EGFR co-mutation.A 64-year-old woman was diagnosed with thoracolumbar and bilateral local rib bone metastases,bilateral pulmonary nodules,and pericardial and left pleural effusion.The pathological diagnosis was lung adenocarcinoma.To seek potential therapeutic regimens,rare co-mutation comprising rare EGFR G724S/R776H mutations and amplification were identified.The patient experienced a significant clinical response with a progression-free survival of 17 mo.CONCLUSION A case of non-small cell lung cancer with rare EGFR G724S/R776H mutations and EGFR amplification responds well to TKI treatment. 展开更多
关键词 EGFR G724S and R776H AFATINIB Non-small cell lung cancer Case report
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部